Latuda (Lurasidone)

Lurasidone is used in psychiatric disorders that involve dopamine and serotonin dysregulation.

• Schizophrenia: reduces positive and negative symptoms, improving overall functioning.
• Bipolar I disorder (depressive episodes): alleviates depressive symptoms and helps maintain mood stability.

• Lurasidone acts as an antagonist at dopamine D2 and serotonin 5‑HT2A receptors, while partially agonizing 5‑HT1A and antagonizing 5‑HT7 receptors. This combined activity balances dopaminergic and serotonergic neurotransmission, leading to reduced psychotic symptoms and stabilization of mood in affected patients.

Lurasidone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Akathisia: inner restlessness or urge to move.
• Somnolence: increased sleepiness or fatigue.
• Weight gain: modest increase in body weight.
• Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity.
• Tardive dyskinesia: persistent involuntary movements, potentially irreversible.
• Seizures: occasional occurrence, especially in predisposed individuals.

Before initiating therapy, clinicians should consider several safety aspects.

• Cardiovascular assessment: evaluate for orthostatic hypotension and QT‑interval prolongation risk.
• Metabolic monitoring: regularly check weight, glucose, and lipid levels.
• Hepatic function: adjust use in patients with moderate liver impairment.
• Suicidal ideation: monitor for emergence of suicidal thoughts, particularly early in treatment.
• Discontinuation: avoid abrupt cessation to reduce risk of relapse or withdrawal phenomena.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lurasidone can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase lurasidone plasma levels.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can substantially reduce drug exposure.
• Other antipsychotics: concurrent use may heighten the risk of QT prolongation and extrapyramidal symptoms.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may exacerbate dry mouth and constipation.
• CNS depressants (e.g., benzodiazepines, alcohol): can increase sedation and impair psychomotor performance.
• Antihypertensive drugs: additive hypotensive effects may occur.